NCT03383614View on ClinicalTrials.gov

Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

October 15, 2018

Study Completion Date

October 15, 2018

Conditions
Filariasis
Interventions
DRUG

LSF emodepside (BAY 44-4400) or matching placebo

Emodepside administered as an LSF oral solution (1mg/mL)

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research Limited, London

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Drugs for Neglected Diseases

OTHER